Get the free Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein - dtic

This is an annual report detailing the evaluation and development of molecular inhibitors targeting the c-Myc oncoprotein, which is linked to various forms of human cancers. The report outlines research

How to fill out evaluation of molecular inhibitors

How to fill out Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein

1. Gather relevant background information on c-Myc and its role in cancer biology.
2. Identify the molecular inhibitors that you will evaluate.
3. Design the experimental setup, including control and treated groups.
4. Outline the methods for assessing the efficacy of the inhibitors, such as cell viability assays or apoptosis assays.
5. Prepare the necessary reagents and materials for the experiments.
6. Conduct the experiments following proper protocols, ensuring accurate data collection.
7. Analyze the data collected to determine the effectiveness of the inhibitors.
8. Document your findings comprehensively, including any observations or unexpected results.
9. Prepare a report summarizing the evaluation, including figures and tables for clarity.

Who needs Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

1. Researchers studying cancer biology to understand the role of c-Myc in tumor progression.
2. Pharmaceutical companies developing new cancer therapies targeting the c-Myc pathway.
3. Clinical oncologists looking for potential treatment options for patients with c-Myc driven tumors.
4. Academic institutions offering advanced studies in molecular biology and pharmacology.

People Also Ask about

What is the function of the C-MYC?

The c-Myc gene serves as a “master regulator” of cellular metabolism and proliferation. Since it is activated by a large number of oncogenic pathways and, in turn, stimulates many of the metabolic changes that result in malignant transformation, it is truly “both the chicken and the egg”.

What does MYC inhibitor do?

In vivo studies show that MYC inhibition elicits a prominent anti-proliferative effect and sustained tumor regression while any alteration on healthy tissue remains reversible. This opens an exploitable window for treatment that makes MYC one of the most appealing therapeutic targets for cancer drug development.

What is the function of the MYC factor?

A well-known fundamental function of MYC is induction of apoptosis. MYC transcription factor has a dual role in tumor cells. It can activate and repress various downstream pathways that can induce proliferation or apoptosis [6].

What is the MYC gene responsible for?

MYC regulates the expression of gene products through direct activation or inhibition of gene transcription,5 transcriptional amplification,3,4,13 the induction of microRNA and chromatin regulators,14,15 and/or the global regulation of RNA and protein biogenesis.

Which disease is associated with MYC?

Abstract. The proto-oncogene Myc serves as a paradigm for understanding the dynamics of transcriptional regulation. Myc protein has been linked to immune dysfunction, cancer development and neoplastic transformation.

What is the C-myc mutation seen in?

c-myc is often rearranged in tumors resulting in deregulated expression. In addition, mutations in the coding region of c-myc are frequently found in human lymphomas, a hot spot being the Thr58 phosphorylation site, a mutation shown to enhance the transforming capacity of c-Myc.

What does the MYCN gene do?

The MYCN protein regulates the activity of other genes by attaching (binding) to specific regions of DNA and controlling the first step of protein production (transcription). On the basis of this action, this protein is called a transcription factor. The MYCN gene belongs to a class of genes known as oncogenes.

What is the function of normal MYC?

The N-terminal region will bind with co-activator complexes, making MYC acts as the transcription or repression factor (Cowling et al 2006). In normal cells, MYC is tightly regulated by mitotic and developmental signals, and in turn, it regulates the expression of downstream target genes.

What cancer is associated with MYC?

MYC is frequently translocated in multiple myeloma (Shou et al., 2000) and is one of the most highly amplified oncogene among many different human cancers (Beroukhim et al., 2010). Defects in the Wnt-APC pathway found in human colon carcinoma results in enhanced TCF transcriptional activation of MYC (He et al., 1998).

What is MYC inhibitor?

Among the 'most wanted' targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein.

For pdfFiller’s FAQs

What is Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein refers to the assessment and analysis of compounds that can hinder the activity of the c-Myc protein, which is involved in cell proliferation and can contribute to cancer development.

Who is required to file Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

Researchers, pharmaceutical companies, and organizations involved in cancer research or drug development are typically required to file evaluations regarding molecular inhibitors of the c-Myc oncoprotein.

How to fill out Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

To fill out the evaluation, one must provide detailed information on the molecular inhibitors being studied, including data on their chemical properties, mechanism of action, efficacy, safety profiles, and results from preliminary studies or clinical trials.

What is the purpose of Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The purpose is to understand the effectiveness and safety of inhibitors targeting the c-Myc oncoprotein in order to develop new therapeutic strategies for cancers that are driven by c-Myc dysregulation.

What information must be reported on Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The report should include information on the inhibitors' molecular structure, biological activity, binding affinity, mechanisms of action, results from efficacy studies, toxicity profiles, and any pertinent clinical data.